John Overdeck’s Context Therapeutics CNTX Stock Holding History

John Overdeck’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.4K	Buy	+25,941	New	+$52.6K	﹤0.01%	4995
2024 Q4	–	Sell	-13,844	Closed	-$27.1K	–	3245
2024 Q3	$27.1K	Hold	13,844	–	–	﹤0.01%	3010
2024 Q2	$27.8K	Buy	+13,844	New	+$23.9K	﹤0.01%	2923
2023 Q3	–	Sell	-26,839	Closed	-$42.9K	–	2983
2023 Q2	$42.9K	Sell	26,839 -28,849	-52%	-$24.5K	﹤0.01%	2843
2023 Q1	$31.3K	Buy	55,688 +29,154	+110%	+$22.1K	﹤0.01%	2810
2022 Q4	$17.3K	Sell	26,534 -29,997	-53%	-$32.3K	﹤0.01%	2693
2022 Q3	$63K	Buy	+56,531	New	+$102K	﹤0.01%	2292

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

John Overdeck's CNTX Position: Q2 2026 in Review

John Overdeck opened a new position in Context Therapeutics (CNTX) in Q2 2026: 25,941 shares worth $14.4K. The stake represents ﹤0.01% of the portfolio and ranks #4995 among its holdings. This is a return to the name: John Overdeck previously reported a position in CNTX as recently as Q3 2024.

John Overdeck first reported a position in CNTX in Q3 2022 and has held it in 7 quarters since. The position peaked at $63K in Q3 2022. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

John Overdeck held 25,941 shares of Context Therapeutics worth $14.4K as of Q2 2026.
Context Therapeutics was a new John Overdeck position in Q2 2026.
Context Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4995 holding.
John Overdeck first reported a position in Context Therapeutics in Q3 2022 and has held it in 7 quarters since.
John Overdeck's Context Therapeutics position peaked at $63K in Q3 2022.
79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.